The newspaper reviewed public records and discovered Amazon holds licenses in at least 12 states: Alabama, Arizona, Connecticut, Idaho, Louisiana, Michigan, Nevada, New Hampshire, New Jersey, North Dakota, Oregon and Tennessee. The company also has an application pending in Maine, according to the report.
It’s not clear whether the licenses reflect Amazon’s potential involvement in the drug supply chain. However, Leerink Partners analyst Ana Gupte said the move “strengthens our conviction on the likely entry into the drug supply chain,” according to the Post-Dispatch.
“It is still not clear if [Amazon] will pursue a buy or partner with an existing [pharmacy benefit manager] or build such capabilities from within,” she added.
Amazon declined the Post-Dispatch’s request for comment.
More articles on supply chain:
FDA hires Mylan exec as senior communications adviser
63% of employers say PBMs not transparent about how they make
money
Pfizer to auction off consumer health unit in November, sources say
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
